Sugi Predict

Sugi Predict / Compounds / SCHEMBL327252

SCHEMBL327252

SCHEMBL327252

N=C(N)Nc1ccc(CN)cc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 3/20 0.54
▸ F10 P00742 1/20 0.54
▸ PLG P00747 5/20 0.51
▸ KLKB1 P03952 4/20 0.51
▸ PLAU P00749 2/20 0.51
▸ PLAT P00750 1/20 0.51
▸ PRSS1 P07477 1/20 0.51
▸ ABAT P80404 1/20 0.44
▸ KLK1 P06870 4/20 0.44
▸ KLK6 Q92876 4/20 0.44
▸ HRH3 Q9Y5N1 1/20 0.42
▸ NOS3 P29474 1/20 0.41
▸ NOS1 P29475 1/20 0.41
▸ NOS2 P35228 1/20 0.41
▸ ST14 Q9Y5Y6 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7443406 0.98 LOXL2 (0.52) LOXL2F10PLGKLKB1PLAU
Trifluoroacetic Acid SCHEMBL7417053 0.85 ITGB3 (0.53) LOXL2F10PLGKLKB1PLAU
SCHEMBL3785285 0.84 AOC3 (0.45) PRSS1HRH3NOS1ST14
SCHEMBL1743186 0.84 ADRA2A (0.50) PRSS1ST14
SCHEMBL27823829 0.84 LOXL2 (0.47) LOXL2F10PLGKLKB1PLAU
SCHEMBL1996992 0.83 F2 (0.50) PRSS1ST14
SCHEMBL13911596 0.83 TAAR1 (0.48) LOXL2NOS3NOS1NOS2
SCHEMBL20553484 0.83 PRSS1 (0.54) PLGKLKB1PLAUPLATPRSS1
SCHEMBL3772999 0.81 GRIN2D (0.58) PLGKLKB1PLAUPLATPRSS1
Hydrochloric Acid SCHEMBL6157588 0.81 PRSS1 (0.52) PLGKLKB1PLAUPLATPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160257708-A1 ACYLATED 4-AMIDINO- AND 4-GUANIDINOBENZYLAMINES FOR THE INHIBITION OF PLASMA KALLIKREIN CURACYTE CHEMISTRY GMBH (DE) 2016-09-08 — — US claimed
EP-1583526-B1 ACYLATED 4-AMIDINO- AND 4-GUANIDINOBENZYLAMINES FOR THE INHIBITION OF PLASMA KALLIKREIN MEDICINES CO LEIPZIG GMBH (DE) 2012-09-05 — — EP claimed
EP-2340822-A1 Acylated 4-amidino and 4-guanidinobenzylamines for inhibiting plasma kallikreins The Medicines Company (Leipzig) GmbH (DE) 2011-07-06 — — EP claimed
US-20060148901-A1 Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2006-07-06 — — US claimed
JP-2006516277-A — — 2006-06-29 — — JP claimed
EP-1583526-A1 ACYLATED 4-AMIDINO- AND 4-GUANIDINOBENZYLAMINES FOR THE INHIBITION OF PLASMA KALLIKREIN Curacyte Chemistry GmbH (DE) 2005-10-12 — — EP claimed
WO-2004062657-A1 ACYLATED 4-AMIDINO- AND 4-GUANIDINOBENZYLAMINES FOR THE INHIBITION OF PLASMA KALLIKREIN CURACYTE CHEMISTRY GMBH (DE) 2004-07-29 — — WO claimed
US-12595279-B2 Modified nucleoside and synthetic methods thereof Stemirna Therapeutics Co., Ltd. (CN) 2026-04-07 — — US disclosed
CN-121204856-A Cool feeling breathable fiber and preparation method thereof 南通德卡纺织科技有限公司 2025-12-26 — — CN disclosed
US-11912794-B2 Modulation of structured polypeptide specificity Bicyclerd Limited (GB) 2024-02-27 — — US disclosed
US-11753444-B2 Modulation of structured polypeptide specificity Bicyclerd Limited (GB) 2023-09-12 — — US disclosed
US-20230146239-A1 GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS THE SCRIPPS RESEARCH INSTITUTE (US) 2023-05-11 — — US disclosed
CN-114096550-B Modified nucleosides and methods of synthesis thereof 斯微(上海)生物科技股份有限公司 2023-04-14 — — CN disclosed
WO-2003076391-A2 UROKINASE INHIBITORS, PRODUCTION AND USE THEREOF CURACYTE AG (DE) 2003-09-18 — — WO disclosed
US-20030166576-A1 Urokinase inhibitors WILEX AG (DE) 2003-09-04 — — US disclosed
EP-1286673-A2 LIGANDS OF INTEGRIN RECEPTORS Basf Aktiengesellschaft (DE) 2003-03-05 — — EP disclosed
CN-1374960-A novel integrin receptor antagonists BASF AG (DE) 2002-10-16 — — CN disclosed
EP-1202988-A2 NOVEL INTEGRIN RECEPTOR ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 2002-05-08 — — EP disclosed
WO-2001093840-A2 LIGANDS OF INTEGRIN RECEPTORS BASF AG (DE) 2001-12-13 — — WO disclosed
WO-2001010847-A2 NOVEL INTEGRIN RECEPTOR ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 2001-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166576-A1 Urokinase inhibitors PLAU, PLAUR, PLAT LOXL2 508/4885F10 186/4885PLG 5/4885
US-20060148901-A1 Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein F12, F11, F2 LOXL2 2598/4885F10 15/4885PLG 27/4885
US-20230146239-A1 GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS RNMT, RNGTT, CAPG LOXL2 3748/4885F10 4187/4885PLG 498/4885
US-20160257708-A1 ACYLATED 4-AMIDINO- AND 4-GUANIDINOBENZYLAMINES FOR THE INHIBITION OF PLASMA KALLIKREIN F12, F2, F11 LOXL2 2608/4885F10 15/4885PLG 29/4885
US-12595279-B2 Modified nucleoside and synthetic methods thereof RNMT, NSUN2, RNGTT LOXL2 4566/4885F10 920/4885PLG 4582/4885
US-11753444-B2 Modulation of structured polypeptide specificity KLKB1, KLK5, KLK1 LOXL2 4287/4885F10 464/4885PLG 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.